These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 31863899)

  • 1. Resistance to ceftazidime-avibactam and underlying mechanisms.
    Wang Y; Wang J; Wang R; Cai Y
    J Glob Antimicrob Resist; 2020 Sep; 22():18-27. PubMed ID: 31863899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.
    Fröhlich C; Sørum V; Thomassen AM; Johnsen PJ; Leiros HS; Samuelsen Ø
    mSphere; 2019 Mar; 4(2):. PubMed ID: 30918055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibility testing of Enterobacteriaceae: determination of disk content and Kirby-Bauer breakpoint for ceftazidime/avibactam.
    Yang X; Wang D; Zhou Q; Nie F; Du H; Pang X; Fan Y; Bai T; Xu Y
    BMC Microbiol; 2019 Nov; 19(1):240. PubMed ID: 31675928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of ceftazidime-avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance.
    López-Hernández I; Alonso N; Fernández-Martínez M; Zamorano L; Rivera A; Oliver A; Conejo MC; Martínez-Martínez L; Navarro F; Pascual A
    Enferm Infecc Microbiol Clin; 2017 Oct; 35(8):499-504. PubMed ID: 27887765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
    Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
    Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro activity of ceftazidime-avibactam combined with colistin against extensively drug-resistant Pseudomonas aeruginosa].
    Mei Q; Geng S; Fang X; He Y; Liu L; Xu M; Zhu C; Pan A
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Oct; 31(10):1212-1218. PubMed ID: 31771717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
    Zhang P; Shi Q; Hu H; Hong B; Wu X; Du X; Akova M; Yu Y
    Clin Microbiol Infect; 2020 Jan; 26(1):124.e1-124.e4. PubMed ID: 31494252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam.
    Xiong L; Wang X; Wang Y; Yu W; Zhou Y; Chi X; Xiao T; Xiao Y
    WIREs Mech Dis; 2022 Nov; 14(6):e1571. PubMed ID: 35891616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of Chromatic Super CAZ/AVI
    Bianco G; Boattini M; Comini S; Leone A; Bondi A; Zaccaria T; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Sep; 41(9):1165-1171. PubMed ID: 35933457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of ceftazidime/avibactam against Gram-negative strains in Colombia 2014-2018.
    Lemos-Luengas EV; Rentería-Valoyes S; Cárdenas-Isaza P; Ramos-Castaneda JA
    J Glob Antimicrob Resist; 2022 Jun; 29():141-146. PubMed ID: 35257971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.
    Krapp F; Grant JL; Sutton SH; Ozer EA; Barr VO
    Int J Antimicrob Agents; 2017 Jun; 49(6):770-773. PubMed ID: 28389354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
    Gaibani P; Lewis RE; Volpe SL; Giannella M; Campoli C; Landini MP; Viale P; Re MC; Ambretti S
    Int J Infect Dis; 2017 Dec; 65():1-3. PubMed ID: 28951106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.
    Temkin E; Torre-Cisneros J; Beovic B; Benito N; Giannella M; Gilarranz R; Jeremiah C; Loeches B; Machuca I; Jiménez-Martín MJ; Martínez JA; Mora-Rillo M; Navas E; Osthoff M; Pozo JC; Ramos Ramos JC; Rodriguez M; Sánchez-García M; Viale P; Wolff M; Carmeli Y
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of ceftazidime-avibactam against gram-negative bacteria in patients with bacteremia and skin and soft-tissue infections in Colombia 2019-2021.
    Lemos-Luengas EV; Rentería-Valoyes S; Muñoz DMA; Gonzalez CKG; Guerrón-Gómez G; Ramos-Castaneda JA
    Diagn Microbiol Infect Dis; 2024 Jun; 109(2):116235. PubMed ID: 38458096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella
    Guo Y; Liu N; Lin Z; Ba X; Zhuo C; Li F; Wang J; Li Y; Yao L; Liu B; Xiao S; Jiang Y; Zhuo C
    Emerg Microbes Infect; 2021 Dec; 10(1):2042-2051. PubMed ID: 34551677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program.
    Lin LY; Debabov D; Chang W; Stone G; Riccobene T
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0198521. PubMed ID: 35225651
    [No Abstract]   [Full Text] [Related]  

  • 18. Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.
    Zhen S; Wang H; Feng S
    Infection; 2022 Dec; 50(6):1409-1423. PubMed ID: 35781869
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Barnes MD; Winkler ML; Taracila MA; Page MG; Desarbre E; Kreiswirth BN; Shields RK; Nguyen MH; Clancy C; Spellberg B; Papp-Wallace KM; Bonomo RA
    mBio; 2017 Oct; 8(5):. PubMed ID: 29089425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro.
    Lin Q; Zou H; Chen X; Wu M; Ma D; Yu H; Niu S; Huang S
    BMC Microbiol; 2021 Feb; 21(1):60. PubMed ID: 33618662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.